| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 16 Nov 2026 | SCHEDULE 13G/A |
| 16 Nov 2026 | SCHEDULE 13G/A |
| 10 Nov 2026 | SCHEDULE 13G |
| 05 Nov 2026 | 10-Q |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
TRUTAKNA® (atacicept-vymj) U.S. launch building early momentum following July 7 accelerated approval by the U.S. Food and Drug Administration (FDA) with approximately 700 Patient Start Forms (PSFs) to date and $10.3 million of net produc... |
| 17 Sep 2026 |
Form 4: Fordyce Marshall, Director
Received 18,500 shares by exercise or conversion ($53.6K) · Sold 18,500 shares ($685K) |
| 15 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
Exhibit 99.2 Corporate Presentation Sep temb er 2026 © 2026 Vera Therapeutics, Inc. Corporate Presentation |
| 14 Sep 2026 |
Form 4: Young Joseph R, SVP, FINANCE, CHIEF ACCT OFFCR
Received 5,000 shares by exercise or conversion ($19.7K) |
| 04 Sep 2026 |
Form 4: Fordyce Marshall, Director
Received 18,500 shares by exercise or conversion ($53.6K) · Sold 18,500 shares ($650K) |
| 02 Sep 2026 | 144 |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 12 Aug 2026 |
Form 4/A: Fordyce Marshall, Director
Received 46,250 shares by exercise or conversion ($134K) · Sold 46,250 shares ($1.96M) |
| 12 Aug 2026 |
Form 4/A: Fordyce Marshall, Director
Received 18,500 shares by exercise or conversion ($53.6K) · Sold 18,500 shares ($702K) |
| 12 Aug 2026 |
Form 4/A: Fordyce Marshall, Director
Received 18,500 shares by exercise or conversion ($53.6K) · Sold 18,500 shares ($680K) |
| 10 Aug 2026 | 10-Q |
| 10 Aug 2026 |
8-K: Results of Operations and Financial Condition
TRUTAKNA™ granted accelerated approval by U.S. Food and Drug Administration (FDA) in adult patients with primary IgA nephropathy (IgAN) at risk for disease progression. |
| 07 Aug 2026 | SCHEDULE 13G |
| 05 Aug 2026 |
Form 4: Boman Nancy Lee, Chief Regulatory Officer
Received 44,987 shares as a grant or award · Granted 63,011 Stock Option (right to buy) |
| 05 Aug 2026 |
Form 3: Boman Nancy Lee, Chief Regulatory Officer
No securities owned |
Loading...